Figure 6.

In vivo antitumor activity of Abs, ADC and small molecule drugs in NCI-N87 xenograft models. (A) In vivo tumor inhibition effect of the first run treatment. Hertuzumab-MMAE was given as a single intravenous injection at doses of 2.5, 5 or 10 mg/kg on day 0. Herceptin (10 mg/kg) was injected intravenously on days 0, 7, and 14. Lapatinib (200 mg/kg) was given daily through intragastric administration from day0 to day20. (B) In vivo tumor inhibition effect of the second run treatment. The effects of hertuzumab-vcMMAE (0.5 or 5 mg/kg), hertuzumab (5 mg/kg), free MMAE (0.1 mg/kg equivalent of 5 mg/kg hertuzumab-vcMMAE) mono-treatment, and hertuzumab at 5 mg/kg, MMAE at 0.1 mg/kg co-treatment were evaluated. The mice in all groups were administrated drug at days 0 and 7 after randomization. (C) Subcutaneous tumors in the first run treatment were measured at day 21. (D) Subcutaneous tumors in the second run treatment were measured at day 21